Alexion Pharmaceuticals’ ravulizumab for the prevention of delayed graft function after renal transplantation was granted FDA orphan designation, according to a post on the agency’s website.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Broadcom (AVGO) Stock Slumps as it Packs its Bags for Chinese Investment Push
- Big pharma fears drug price spikes in US-EU tariff spat, Reuters says
- Oppenheimer biotech analyst holds an analyst/industry conference call
- H.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74
- M&A News: AstraZeneca Seals Belgian Firm EsoBiotec Deal to Boost Cell Therapy